SLC2A5 Correlated with Immune Infiltration: A Candidate Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma

Figure 2

SLC2A5 expression in subgroups of clinical characteristics. (a) Expression of SLC2A5 in LUAD based on histological subtypes. (b) Expression of SLC2A5 in LUAD based on patient’s gender. (c) Expression of SLC2A5 in LUAD based on patient’s age. (d) Expression of SLC2A5 in LUAD based on patient’s race. (e) Expression of SLC2A5 in LUAD based on nodal metastasis status. (f) Expression of SLC2A5 in LUAD based on individual cancer stages.

(a)

(b)

(c)

(d)

(e)

(f)